Trials / Unknown
UnknownNCT01069211
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
Assessment of Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 876 (estimated)
- Sponsor
- Korean Breast Cancer Study Group · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess clinical outcomes after Letrozole treatment according to the estrogen receptor expression in postmenopausal women with hormone receptor positive breast cancer.
Detailed description
This study aimed at evaluating following: 1. Validity Assessment: 1. Primary End Point: To evaluate 5-year diseae free survival rate after Letrozole treatment according to the estrogen receptor expression in postmenopausal women 2. Secondary End Point: To evaluate overall survival rate(OS) and Time to distance recurrence(TTDR) after Hormonal therapy in postmenopausal women with hormone receptor positive breast cancer 2. Safety Assessment: To evaluate all adverse events including serious adverse events after Letrozole treatment.
Conditions
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2010-02-17
- Last updated
- 2011-05-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01069211. Inclusion in this directory is not an endorsement.